Evidence map›Paper›PMID 38060062›Full record

ReviewReviews in endocrine & metabolic disorders2024

New findings on brain actions of growth hormone and potential clinical implications.

Jose Donato, John J Kopchick

Open access · greenAbstract readReview
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 22 citations in OpenAlex.

  1. [Multiple clinical effects of recombinant human growth hormone therapy].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  10. Review
  11. Article
  12. GHRH and its analogues in central nervous system diseases.Reviews in endocrine & metabolic disorders · 2025
    Review
  13. Review
  14. Review
  15. Hypothalamic GHRH.Reviews in endocrine & metabolic disorders · 2025
    Review
  16. Article
  17. Article
  18. Growth Hormone, Hypothalamic Inflammation, and Aging.Journal of obesity & metabolic syndrome · 2024
    Review
  19. Growth hormone receptor in VGLUT2 or Sim1 cells regulates glycemia and insulin sensitivity.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Jose DonatoDepartment of Physiology and Biophysics, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Lineu Prestes, 1524, Sao Paulo, SP, 05508-000, Brazil. jdonato@icb.usp.br.ORCID 0000-0002-4166-7608
John J KopchickEdison Biotechnology Institute and Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, 45701, USA.ORCID 0000-0003-4561-2177
Ohio University · USUniversidade de São Paulo · BR

Funding

Modulating Growth Hormone Action as a Target for Improved Health and LongevityR01AG059779 · NIA · OHIO UNIVERSITY ATHENS · PI John Joseph Kopchick · 2018 to 2026
$4.7M
Growth hormone regulating chondrocyte metabolism for osteoarthritis developmentR01AR081804 · NIAMS · OHIO UNIVERSITY ATHENS · PI Shouan Zhu · 2023 to 2026
$2.0M
Diabetes Institute Summer Interprofessional Research Experience (DISIRE) for UndergraduatesR25DK122952 · NIDDK · OHIO UNIVERSITY ATHENS · PI John Joseph Kopchick · 2022 to 2026
$421k
Developing helical peptide antagonists of the growth hormone receptorR21AG081962 · NIA · OHIO UNIVERSITY ATHENS · PI HOLUB, JUSTIN MATTHEW, KOPCHICK, JOHN JOSEPH · 2023 to 2023
$415k
Conselho Nacional de Desenvolvimento Científico e Tecnológico 303363/2019-3Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/01318-8NIAMS NIH HHS R01 AR081804NIA NIH HHS R01 AG059779NIA NIH HHS R21 AG081962NIA NIH HHS R21AG081962NIDDK NIH HHS R25 DK122952NIH HHS 2R01AG059779NIH HHS R01AR081804NIH HHS R25DK122952
6 · The paper itself

Abstract

Growth hormone (GH) is secreted by somatotropic cells of the anterior pituitary gland. The classical effects of GH comprise the stimulation of cell proliferation, tissue and body growth, lipolysis, and insulin resistance. The GH receptor (GHR) is expressed in numerous brain regions. Notably, a growing body of evidence indicates that GH-induced GHR signaling in specific neuronal populations regulates multiple physiological functions, including energy balance, glucose homeostasis, stress response, behavior, and several neurological/cognitive aspects. The importance of central GHR signaling is particularly evident when the organism is under metabolic stress, such as pregnancy, chronic food deprivation, hypoglycemia, and prolonged exercise. These particular situations are associated with elevated GH secretion. Thus, central GH action represents an internal signal that coordinates metabolic, neurological, neuroendocrine, and behavioral adaptations that are evolutionarily advantageous to increase the chances of survival. This review summarizes and discusses recent findings indicating that the brain is an important target of GH, and GHR signaling in different neuronal populations regulates essential physiological functions.

Indexed as

BrainGrowth HormoneReceptors, SomatotropinAnimalsHuman Growth HormoneHumansSignal TransductionGrowth HormoneHuman Growth HormoneReceptors, SomatotropinCentral nervous systemFood restrictionGrowth hormoneHypoglycemiaHypothalamusMetabolism

Identifiers

PMID38060062
PMCPMC11156798
OpenAlexW4389429531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.